Breakthrough AI Innovations Transform Breast Care
GE HealthCare is showcasing its cutting-edge advancements in diagnostic accuracy and patient-centered breast care at the 2025 Society of Breast Imaging Symposium in Colorado Springs, Colorado (April 24-27, 2025). This year’s presentation highlights revolutionary technologies designed to enhance breast cancer detection, optimize clinical workflows, and elevate the standard of patient care.With breast cancer remaining one of the most common cancers diagnosed worldwide, these innovations represent significant progress in the ongoing effort to improve early detection rates and treatment outcomes for millions of women.
Pristina Via: Redefining Mammography Efficiency
The newly unveiled Pristina Via mammography system represents a significant leap forward in breast cancer screening technology. As part of the renowned Senographe Pristina platform, this innovative system delivers effortless acquisition, operational excellence, and clinical confidence—transforming the screening experience for both technologists and patients alike.
Developed specifically with technologists in mind, Pristina Via elevates in-room workflow and patient comfort through:
- Zero-click acquisition functionality when working within protocols
- No waiting time between exposures
- DBT image-to-image cycle times up to twice as fast as competitor systems
- Vendor-neutral prior image comparison capabilities
- Pristina 3D STD mode offering the lowest radiation dose across all tissue thicknesses among major market systems
SmartMammo: AI-Powered Diagnostic Precision
GE HealthCare has expanded its strategic collaboration with DeepHealth Inc, an AI pioneer in health informatics and RadNet subsidiary. This partnership has yielded the commercial availability of SmartMammo, now FDA 510(k) cleared for integration with the Pristina platform in U.S. markets.
SmartMammo’s AI-powered SaaS solution seamlessly integrates into existing diagnostic workflows, delivering:
- Enhanced diagnostic accuracy and workflow efficiencies
- Fast image loading and real-time multimodality data rendering
- Universal workstation accessibility regardless of location
- Direct integration into existing IT infrastructure
- Automatic lesion localization with degree of suspicion indicators
- Proven effectiveness across diverse populations and dense breast tissue
What truly sets SmartMammo apart is its direct integration into existing IT infrastructure, eliminating the need for disruptive overhauls or expensive system replacements. The technology’s automatic lesion localization with degree of suspicion indicators provides radiologists with valuable decision support, highlighting areas of concern that might otherwise be overlooked in dense or complex breast tissue. Extensive clinical validation has demonstrated SmartMammo’s proven effectiveness across diverse populations and dense breast tissue types, addressing a critical gap in traditional mammography screening.
“We are committed to delivering innovative technologies and end-to-end solutions that address our customer’s biggest challenge in breast cancer detection, which is to help clinicians provide efficient, accurate and personalized diagnosis to patients,” says Pooja Pathak, Vice President and General Manager of Mammography at GE HealthCare. “With Pristina Via and SmartMammo, we have streamlined both exam and radiology workflows in breast cancer screening and diagnostics, enabling clinicians to prioritize patient care.”
Comprehensive Breast Imaging Portfolio
Invenia ABUS Premium: Detecting Cancer In Dense Breasts
The Invenia Automated Breast Ultrasound (ABUS) Premium—the first FDA-approved ultrasound specifically designed for dense breast cancer detection as an adjunct to mammography—offers significant advantages:
- Critical for the 40% of women globally and 70% of Asian women with dense breast tissue
- Demonstrates a 35.7% increase in cancer detection when combined with mammography
- Features integrated Verisound™ AI and AI Assistant for faster, reproducible scanning
- Delivers exceptional image quality for increased clinical confidence
- Addresses workflow productivity challenges
Advanced Contrast-Enhanced Solutions
GE HealthCare’s contrast-enhanced technologies further expand diagnostic capabilities:
- SenoBright HD Contrast Enhanced Mammography (CEM): A next-generation mammogram that reduces tissue masking effects, increases tumor signal visibility, enables exams in under seven minutes, and provides immediate answers to patients.
- Serena Bright: An innovative contrast-guided biopsy system allowing providers to visualize lesions using CEM and sample with precision—all using familiar mammography equipment and staff to minimize patient stress during procedures.
Through this comprehensive suite of advanced breast imaging technologies, GE HealthCare continues to demonstrate its commitment to improving early detection, enhancing diagnostic accuracy, and delivering compassionate care for patients worldwide.
Discover the latest Provider news updates with a single click. Follow DistilINFO HospitalIT and stay ahead with updates. Join our community today!
Leave a Reply